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Carolyn M Dancevic and Daniel R McCulloch*Abstract
Arthritis is a multifactorial disease for which current therapeutic intervention with high efficacy remains challenging.
Arthritis predominately affects articular joints, and cartilage deterioration and inflammation are key characteristics.
Current therapeutics targeting inflammatory responses often cause severe side effects in patients because of the
systemic inhibition of cytokines or other global immunosuppressive activities. Furthermore, a lack of primary response
or failure to sustain a response to treatment through acquired drug resistance is an ongoing concern. Nevertheless,
treatments such as disease-modifying anti-rheumatic drugs, biological agents, and corticosteroids have revealed
promising outcomes by decreasing pain and inflammation in patients and in some cases reducing radiographic
progression of the disease. Emerging and anecdotal therapeutics with anti-inflammatory activity, alongside specific
inhibitors of the A Disintegrin-like And Metalloproteinase domain with Thrombospondin-1 repeats (ADAMTS)
cartilage-degrading aggrecanases, provide promising additions to current arthritis treatment strategies. Thus, it is
paramount that treatment strategies be optimized to increase efficacy, reduce debilitating side effects, and
improve the quality of life of patients with arthritis. Here, we review the current strategies that attempt to slow or
halt the progression of osteoarthritis and rheumatoid arthritis, providing an up-to-date summary of pharmaceutical
treatment strategies and side effects. Importantly, we highlight their potential to indirectly regulate ADAMTS
aggrecanase activity through their targeting of inflammatory mediators, thus providing insight into a mechanism
by which they might inhibit cartilage destruction to slow or halt radiographic progression of the disease. We also
contrast these with anecdotal or experimental administration of statins that could equally regulate ADAMTS
aggrecanase activity and are available to arthritis sufferers worldwide. Finally, we review the current literature
regarding the development of synthetic inhibitors directed toward the aggrecanases ADAMTS4 and ADAMTS5,
a strategy that might directly inhibit cartilage destruction and restore joint function in both rheumatoid arthritis
and osteoarthritis.Arthritis
Arthritis is a debilitating degenerative disease of articular
joints and is characterized predominately by articular car-
tilage degradation, alterations to subchondral bone mass,
and localized inflammation. The substantial impact on
health-care budgets in Western nations is evidenced by an
estimated health-care burden of 50 million adults (22%, or
approximately 1 in 5) in the US and, worldwide, an esti-
mated 175 million adults have some form of arthritic dis-
ease [1,2]. Inflammatory cytokines such as IL-1, IL-6, and* Correspondence: daniel.mcculloch@deakin.edu.au
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any medium, provided the original work is propTNF-α expressed locally in the articular joint cause inflam-
mation, stimulating the production of cartilage-degrading
zinc-dependent matrix metalloproteinases (MMPs) such
as MMP-1, MMP-2, MMP-3, MMP-9, and MMP-13 and
the A Disintegrin-like And Metalloproteinase domain with
Thrombospondin-1 repeats (ADAMTS) enzymes, pre-
dominately ADAMTS4 and ADAMTS5 or the ‘aggreca-
nases’ [3,4].Roles of matrix metalloproteinases and ADAMTS in
cartilage formation
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equilibrium favors the catabolism of cartilage whereby
protease activity outweighs their inhibition by tissue in-
hibitors of metalloproteinases (TIMPs). Although MMP
and ADAMTS enzymes are responsible for the degrad-
ation of cartilage in arthritic disease, their roles in car-
tilage development and remodeling are crucial for joint
formation and homeostasis. MMP-1 and −2 are local-
ized in synovium and joint articular surfaces in human
fetal limbs at 7 to 14 weeks’ gestation, suggesting roles
for these proteases in the development and remodeling of
synovial tissue and articular cartilage [5]. Studies using
homozygous Mmp-9-null mice revealed its requirement
for angiogenesis and ossification of the developing growth
plate since these mice exhibited delayed apoptosis, ossifi-
cation, and vascularization of hypertrophic chondrocytes,
resulting in progressive growth-plate lengthening [6]. Fur-
thermore, Mmp-13-null mice exhibit defects in growth-
plate cartilage with expanded hypertrophic chondrocyte
zones and increased trabecular bone as well as increased
interstitial collagen accumulation, with combinatorial
Mmp-9 and Mmp-13 knockout mice displaying an exacer-
bated phenotype, suggesting synergy between these two
proteases in cartilage and bone formation [7,8]. Import-
antly, mutations inMMP-9 andMMP-13 in humans cause
genetic disorders in bone and cartilage growth and devel-
opmental phenotypes such as metaphyseal dysplasia and
spondyloepimetaphyseal dysplasia, Missouri type [9,10],
which are disorders of abnormal growth and development
of long bones and vertebrae. Mmp-14 (MT1-MMP)-defi-
cient mice display severe skeletal abnormalities, including
impaired vascularization of epiphyseal cartilage, leading to
delayed ossification and hypertrophic zone lengthening,
revealing a role for Mmp-14 in angiogenesis and bone
growth [11]. Significantly, human mutations in MT1-
MMP cause Winchester syndrome, which is associated
with progressive osteolysis, osteoporosis, and joint ero-
sions [12]. It has not yet been established whether
ADAMTS4 or ADAMTS5 has a role in the development
and growth of cartilage and bone, although their expression
is upregulated in arthritic disease. Other ‘aggrecanases’ in-
clude ADAMTS1, ADAMTS9, and ADAMTS15, which
may have roles during cartilage and bone development. Al-
though Adamts1 mRNA is expressed in growth-plate and
articular cartilage during normal mouse development and
is upregulated in hypertrophic differentiation of growth-
plate chondrocytes, it does not play a significant role in
cartilage and bone development and growth [13] or in
arthritis. Adamts9 mRNA is also expressed from 13.5 days
post-coitus during mouse embryogenesis in the perichon-
drium, the proliferative zone in the growth plate and bone
[14], but roles for ADAMTS9 have not yet been elucidated
in cartilage and bone development or in arthritic disease.
Furthermore, ADAMTS15 is expressed in chondrocytesand perichondrium of the synovial joints in the developing
mouse embryo at 15.5 days post-coitus; however, its func-
tion in the joint during development or arthritis has not
yet been elucidated [15]. Aggrecan degradation facilitated
by MMP and ADAMTS enzymes is a process that occurs
within normal and arthritic cartilage, signifying a role for
these proteases in normal turnover as well as in arthritis
[16], whereas structural changes in aggrecan occur during
healthy aging [17].
Enzymatic processing of joint cartilage
MMP activity is upregulated in arthritic cartilage and
synovial fluid [18,19], which correlates with type II colla-
gen cleavage [20]. The collagenases (MMP-1, MMP-8,
and MMP-13) preferentially degrade type II collagen
(collagen II) at Gly775↓776Leu causing loss of its trimeric
structure, exposing it to further degradation [21]. MMP-
2 and MMP-9 (the gelatinases) and MMP-3 (stromely-
sin), which degrade non-collagen matrix components of
the joint, also promote further degradation of denatured
collagen II after cleavage by collagenases [22]. MMPs
also degrade aggrecan; MMP-3, first isolated from hu-
man articular cartilage, cleaves the Asn341↓342Phe bond
of aggrecan in its interglobular domain (IGD) [23,24].
However, it was recently shown that MMP-generated
aggrecan fragments are involved predominately in normal
aggrecan turnover and that their preferred cleavage site is
located C-terminal to the IGD and that these fragments
may have a lesser role in aggrecan degradation in knee in-
juries and osteoarthritis (OA) in human cartilage [25].
In contrast to collagen II degradation by MMPs, aggrecan
degradation by aggrecanases is an early and reversible event
[26]. Furthermore, since aggrecan prevents collagen II deg-
radation and therefore may impart overall cartilage protec-
tion [27,28], inhibiting aggrecan degradation via the
ADAMTS aggrecanases may be a crucial therapeutic strat-
egy to prevent further collagen II degradation. ADAMTS4
and ADAMTS5/ADAMTS11 were first described in 1999
[29-31] and cleave aggrecan in its C-terminal chondroitin
sulphate (CS)-rich domains (Figure 1) at the following sites:
SELE1545↓1546GRGT, KEEE1714↓1715GLGS, TAQE1819↓1820A-
GEG, and ISQE1919↓1920LGQR; however, the most detri-
mental cleavage is thought to occur within its IGD at
TEGE373↓374ARGS (Glu373↓374Ala bond), generating G1-
NITEGE fragments that release the entire CS-rich region
into the synovial fluid compromising joint function
(reviewed in Fosang and colleagues [32]) (Figure 1).
Aggrecanases and their contribution to arthritis
In 2005, two independent landmark studies demonstrated
that ADAMTS5 catalytic inactivation protected mice from
experimentally induced OA and rheumatoid arthritis (RA)
[33,34] but that ADAMTS4-deficient or catalytically inac-
tivated mice did not show this same protection. However,
Figure 1 The destruction of aggrecan and therapies that slow
radiographic progression of arthritis. Full-length aggrecan resides
in the pericellular matrix attached to hyaluronan via link protein.
Hyaluronan is bound to its cell surface receptor CD44 on articular
chondrocytes. ADAMTS4 and ADAMTS5 cleavage (scissors) within
the interglobular domain (IGD) of aggrecan is the most detrimental
to cartilage function in arthritis as it releases the entire chondroitin
sulphate (CS)-modified C-terminus into the synovium. Inhibitors of
cytokine activity or ADAMTS5 may prevent cartilage loss directly.
ADAMTS, A Disintegrin-like And Metalloproteinase domain with
Thrombospondin-1 repeats; DMARD, disease-modifying anti-rheumatic
drug; G, immunoglobulin-like domain; IL, interleukin; KS, keratan
sulphate; NSAID, non-steroidal anti-inflammatory drug; TNF-α, tumor
necrosis factor-alpha.
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sponsible for the cleavage of aggrecan in arthritis in
humans remains controversial. Although ADAMTS5
cleaves aggrecan extensively in human arthritic syno-
vium and is abundant and widely distributed in human
OA cartilage [35], other data have indicated that both
ADAMTS4 and ADAMTS5 cooperate to mediate aggre-
can degradation in human articular cartilage explants [36].
Since arthritis is a disease of the entire joint, ADAMTS4
and ADAMTS5 may have variable activity depending on
their localization and which cytokines are present to
stimulate their gene expression and activation profile. IL-
1α and TNF-α induction of Adamts5 was found to occur
predominately in synovium and the patellar but not in
femoral head or tibial joint cartilage in ex vivo mouse
joints, indicating that ADAMTS5 may not be the predom-
inant aggrecanase in articular cartilage in arthritis but in
fact may affect cartilage indirectly [37]. Furthermore, in
bovine menisci, the gene expression of ADAMTS4 is pref-
erentially upregulated by IL-1α in inner meniscal zones,
whereas the gene expression of ADAMTS5 is preferen-
tially upregulated by TNF-α in outer meniscal zones [38].
In human OA synovium, upregulation of ADAMTS4, un-
like that of ADAMTS5, was IL-1- and TNF-α-dependent,
again exemplifying the fact that ADAMTS5 may be con-
stitutively expressed and more active in joint structures
other than articular cartilage [3]. The differential roles
of the aggrecanases may add complexity to potentialtreatments discussed below. However, evidence of their
cooperative roles in cartilage degradation and common ac-
tivation by inflammatory cytokines suggests that both
ADAMTS4 and ADAMTS5 represent important thera-
peutic targets in arthritis.
Current arthritis treatments
Current strategies for arthritis treatment have favorable
outcomes in patients who adequately respond. However,
many treatment regimens are inadequate because of
poor and often patient-specific efficacy; they also focus on
decreasing pain and inflammation associated with the dis-
ease but often fail to effectively inhibit cartilage destruction
and therefore the progression of the disease. Furthermore,
because many treatments lose efficacy over time, the in-
creasing doses that are often required augment their tox-
icity and side effects. Current efficacious treatments for RA
predominately include disease-modifying anti-rheumatic
drugs (DMARDs) or biological agents such as antibodies,
and corticosteroid intra-articular joint injections and non-
steroidal anti-inflammatory drugs (NSAIDs) are also used
for both RA and OA.
Rheumatoid arthritis
Disease-modifying anti-rheumatic drugs
DMARDs are essentially immunosuppressants used for the
treatment of RA and include methotrexate, sulfasalazine,
hydroxychloroquine, and leflunomide. Methotrexate is the
‘gold standard’ treatment and now a first-line therapy for
RA patients early in the course of their disease, inhibiting
purine and pyrimidine metabolism with its systemic anti-
inflammatory effects (Figure 2) mediated through adeno-
sine metabolism. Methotrexate suppresses proliferation of
synovial fibroblasts, a source of aggrecanase production,
and also modulates cytokine production [39]; therefore,
methotrexate has the potential to slow cartilage destruction
through the inhibition of ADAMTS4 and ADAMTS5 ac-
tivity (Figure 1), although this possibility has yet to be in-
vestigated. Side effects of methotrexate include abdominal
discomfort, alopecia, oral ulcerations, and cytopenia,
which limit its use to low doses, compromising its efficacy
(Table 1). Despite the improvements this treatment has of-
fered, RA often persists after methotrexate regimens, and
the multifactorial nature of RA means that some patients
have a poor response to treatment regardless of the dose
rate and time of administration. Despite the improve-
ments this treatment has offered, the multifactorial nature
of RA means that some patients remain unresponsive re-
gardless of the dose rate and administration time. There-
fore, additional DMARDs or biological agents are often
administered in combination with methotrexate to im-
prove disease outcomes.
Other DMARDs used to treat RA include the anti-malarial
drugs chloroquine, quinachrine, and hydroxychloroquine.
Figure 2 The structure of the articular joint and targeted
arthritis therapeutics. Multifaceted components such as ligaments,
menisci, and articular surfaces of the articular joint confer upon the
joint compression-resistance and load-bearing properties. Arthritis may
ensue if one or more components are compromised. Chondrocytes
(dark blue) and synoviocytes (light blue) are a source of cytokine
production and aggrecanase activity; inflammatory cytokines are
found in synovial fluid of arthritic joints. Emerging therapeutics
such as statins may suppress inflammatory cytokine activity in
synovial fluid, thereby potentially inhibiting cartilage degradation
mediated by ADAMTS4 and ADAMTS5. Disease-modifying
anti-rheumatic drugs (DMARDs), biological agents, corticosteroids,
and non-steroidal anti-inflammatory drugs (NSAIDs) may also
prevent cartilage destruction indirectly by reducing inflammation.
ADAMTS, A Disintegrin-like And Metalloproteinase domain with
Thrombospondin-1 repeats; IL, interleukin; TNF-α, tumor
necrosis factor-alpha.
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too are suppressors of inflammation (Figure 2) and thus
are also useful therapies, especially in the case of sys-
temic lupus erythematosus, in which quinachrine acts
as a potent inhibitor of cytokine diffusion [40]. Sulfa-
salazine belongs to the ‘sulfa’ class of drugs, which in-
cludes a combination of salicylate (main ingredient of
aspirin) and a sulfa antibiotic, and functions by decreas-
ing pain and swelling to improve joint function [41].
Leflunomide is another DMARD whose effects are un-
surprisingly comparable to those of methotrexate [42];
given that it is an immunomodulatory agent that also
inhibits de novo pyrimidine synthesis, it also has the po-
tential to indirectly inhibit ADAMTS4 and ADAMTS5
aggrecanase activity and cartilage destruction by redu-
cing cytokine production (Figure 1). However, like
methotrexate, these DMARDs have common and often
unacceptable side effects such as diarrhea, nausea, alo-
pecia, vomiting, hepatotoxicity, and infection (Table 1).
Biological agents
Biological agents used to treat arthritis comprise antibodies
against inflammatory cytokines or their receptors to sup-
press their activity, and their use in RA is predominant.
TNF-α inhibitors are the longest existing biological therap-
ies and include adalimumab, entanercept, infliximab, andgolimumab; they are the next line of defense either after or
in combination with DMARD treatments. TNF-α inhibitor
therapy precedes the discovery of the role of ADAMTS4
and ADAMTS5 in cartilage destruction; however, it is now
apparent that inhibiting TNF-α may lead to a reduction in
aggrecanase activity (Figure 1). Indeed, clinical trials dem-
onstrated that TNF-α inhibitor administration in combin-
ation with methotrexate resulted in improvements in the
symptoms of RA, including slowed radiographic disease
progression in the majority of patients with active RA
[43-45], an effect that could be attributable to reduced
ADAMTS4 and ADAMTS5 aggrecanase activity. These
inhibitors included etanercept, a human soluble and di-
meric TNF type II receptor linked to an IgG1-Fc moiety
that binds to and inactivates TNF-α [45], and golimumab,
a humanized anti-TNF-α monoclonal antibody that has a
high selectivity for human TNF-α, also effectively neutral-
izing its activity [44]. Other examples of efficacious TNF-α
inhibitors include the human IgG1 monoclonal antibody
adalimumab that binds specifically to TNF-α, preventing
bioavailability to its p55 and p75 receptors [46], and
infliximab, which is a chimeric (human-mouse) mono-
clonal antibody against human TNF and (like the above
anti-TNF-α antibodies) has had success with symptom-
atic relief and improving quality of life in patients with
RA [47]. However, despite the high efficacy of TNF-α
inhibitors, approximately 30% of patients with RA have
an unsatisfactory response [48], and side effects include
nausea, upper respiratory tract infections, dyspepsia,
and headaches (Table 1).
After failure of responsiveness to TNF-α inhibitors, other
biological agents have been trialed with some success.
These include rituximab (B-cell inhibitor), abatacept (T-cell
inhibitor), tocilizumab (IL-6 inhibitor), and anakinra (IL-1
inhibitor) (Table 1). Treatment with tocilizumab, a human
monoclonal anti-IL-6 receptor antibody that competitively
inhibits the binding of IL-6 to its receptor [43,48], has
demonstrated a significant reduction in symptoms of RA
compared with DMARDs alone or in combination with
methotrexate or other DMARDs [43]. Tocilizumab and
anakinra are of particular interest to aggrecanase biology
given that activities of ADAMTS4 and ADAMTS5 are
regulated by IL-6 and IL-1 (Figure 1).
Abatacept, on the other hand, prevents T cells from
recognizing antigen-presenting cells, as it comprises a
fused Fc domain of IgG with human T-lymphocyte anti-
gen 4. Abatacept has proven to be as effective as other
biological agents in patients who failed to respond to
TNF-α inhibitors. Emery [49] provided an excellent re-
view of clinical data underlying those and previous trials
of non-TNF-α inhibitor responders. Rituximab, a chimeric
monoclonal antibody that leads to peripheral B-cell deple-
tion by blocking the cell surface antigen CD20, demon-
strated greater improvement in patients who had also
Table 1 Current and emerging arthritis treatments and their mode of action and side effects
Therapeutic agent Mode of action Side effects
DMARDs
Methotrexate [39] Inhibits purine and pyrimidine synthesis
and suppresses cytokine synthesis
Abdominal discomfort, alopecia, oral ulcerations
and cytopenia, diarrhea, nausea, alopecia,
vomiting, hepatotoxicity, and infections
Chloroquine, quinachrine, and
hydroxychloroquine [40]
Anti-inflammatory, inhibition
of cytokine diffusion
Sulfasalazine [41] Decreases pain and swelling
Leflunomide [42] Inhibits de novo pyrimidine synthesis
Biological agents
Infliximab [47,54] TNF inhibitors Nausea, upper respiratory tract infections,
dyspepsia, and headaches
Golimumab [44]
Adalimumab [46]
Etanercept [45]
Rituximab [50] B-cell inhibitor (CD20)
Abatacept T-cell inhibitor
Tocilizumab [43,48] IL-6R inhibitor
Anakinra IL-1R inhibitor
Corticosteroids/NSAIDs
Prednisolone [54] Anti-inflammatory Weight gain, immunosuppression, altered glycemic
control, glaucoma, hypertension, and osteoporosis
Aspirin (acetylsalicylic acid) Anti-inflammatory Gastrointestinal ulcer perforation and bleeding,
renal impairment, and platelet dysfunction
Ibuprofen Anti-inflammatory
Naproxen Anti-inflammatory
Therapeutic agent Mode of action Key observations
Statins
Simvastatin [56-58,66] Anti-inflammatory Suppression of macrophage infiltration and bone
destruction (rat), decreased MMP-3 (rat), decreased
migration and invasion of fibroblast-like synoviocytes
(cells), and mild improvements in DAS28 scores
and swollen joint counts (human)
Atorvastatin [59,60,64] Anti-inflammatory Cartilage
anabolism Cartilage protection
Decreased systemic TNF-α (human); reduction
in C-reactive protein and erythrocyte sedimentation
and improved DAS28 scores (human); and decreased
IL-1β and MMP-13 and increased aggrecan and ColIIa1
(in vitro human osteoarthritic chondrocytes)
Rosuvastatin [63] Anti-inflammatory Reduction of C-reactive protein (human)
Mevastatin [65] Anti-inflammatory Cartilage protection Reduction in IL-1β, MMP-3, and MMP-13 (rabbit)
Common arthritis treatments that target inflammation and pain are shown. Disease-modifying anti-rheumatic drugs (DMARDs) used for rheumatoid arthritis target
systemic inflammation, whereas biological agents target localized inflammatory cytokines. Corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) are
often used for both rheumatoid arthritis and osteoarthritis treatments. Cholesterol-lowering drugs (statins) target inflammation and prevent cartilage breakdown
in varying rheumatoid arthritis and osteoarthritis contexts. DAS28, Disease Activity Score in 28 Joints; IL, interleukin; MMP, matrix metalloproteinase; TNF, tumor
necrosis factor.
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placebo in a phase III study [50]. In combination with
background methotrexate, rituximab treatment resulted in
significant improvement in most disease scores; however,
patients did suffer mild to moderate side effects, including
low rates of infection.
As discussed above, IL-1, IL-6, and TNF-α are all reg-
ulators of ADAMTS4 and ADAMTS5 levels and activity
and thus indirectly stimulate cartilage destruction.Therefore, any biological agent that targets systemic or
local mediators of inflammation has the potential to in-
hibit cartilage destruction through regulating the bio-
availability or bioactivity (or both) of ADAMTS4 and
ADAMTS5. In most of the cases of the biological agents
outlined above, which are currently used in the clinic,
slowed radiographic disease progression has been dem-
onstrated, strongly suggesting that aggrecanase activity
was concurrently suppressed.
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Corticosteroids and non-steroidal anti-inflammatory drugs
Glucocorticoids such as prednisolone are steroidal-based
drugs administered orally or by intra-articular injection
and have immunomodulatory properties and potent sys-
temic and local anti-inflammatory effects, offering another
treatment option for both OA and RA (Figure 2). Their
short-term use is often indicated in acute joint injuries,
joint replacement surgery, and tendonitis to suppress in-
flammation [51-53]. It has been suggested that glucocorti-
coids, often used in combination with DMARDs in RA,
may be just as powerful in combination with a DMARD
as a biological agent such as infliximab [54]. Glucocorti-
coids are used to manage acute pain and inflammation as
they inhibit nuclear factor-kappa-B (NF-κB), a potent me-
diator of cytokine signaling. Given their immunosuppres-
sive properties, glucocorticoids are also likely to lead to
the suppression of ADAMTS4 and ADAMTS5 aggreca-
nase activity (Figure 1). Their disease-modifying properties
have become more apparent recently; they may slow the
progression of the disease, even after halting treatment
[54]. However, although glucocorticoids are often quite
effective, their adverse effects are problematic and in-
clude weight gain, osteoporosis, immunosuppression,
altered glycemic control, glaucoma, fractures, muscle
wasting, and hypertension (Table 1), which are counter-
balanced by using the lowest possible dose for the short-
est period of time.
NSAIDs such as aspirin (acetylsalicylic acid), ibuprofen,
naproxen, and mobic are recommended as the first line of
treatment in inflammatory arthritis because of their pain-
and stiffness-relieving properties but also are an effective
treatment for OA. They inhibit cyclooxygenase (COX),
and some are specific to COX-2, which catalyzes the syn-
thesis of prostaglandins. Recent evidence demonstrates
that celecoxib, a selective COX-2 inhibitor, can diminish
cyclic tensile strain-induced upregulation of ADAMTS5
and increase aggrecan expression in porcine mandibular
chondrocytes [55], suggesting that NSAIDs may provide
dual inhibition of inflammation and cartilage destruction.
However, there are concerns about their long-term safety
and efficacy as they are associated with toxicity and their
adverse effects are dose-dependent and include gastro-
intestinal ulcer perforation and bleeding, renal impair-
ment, and platelet dysfunction (Table 1).
Statin therapy: an emerging treatment for
rheumatoid arthritis and osteoarthritis
Statins - 3-hydroxy-3-methylglutaryl coenzyme A reduc-
tase inhibitors, including atorvastatin, mevastatin, prava-
statin, and simvastatin - have roles predominately in
cholesterol reduction and are effective in reducing cardio-
vascular morbidity and mortality. However, they also ap-
pear to have pleiotropic actions independent of theircholesterol-lowering properties such as anti-inflammatory
effects, as demonstrated in experimental models of arth-
ritis as well as in human trials (Table 1).
Rheumatoid arthritis
There is evidence to suggest that statins have strong anti-
inflammatory effects in RA. Simvastatin decreased articular
macrophage infiltration and suppressed bone destruction in
an RA rat model [56]. Furthermore, simvastatin inhibited
the migration and invasion of fibroblast-like synoviocytes
by preventing the activation of RhoA, a small GTP-binding
protein known to activate NF-κB, therefore identifying a
novel therapeutic agent for RA [57]. A prospective study in
patients with RA demonstrated that 20 mg/day of simva-
statin was a safe treatment that had anti-inflammatory ef-
fects with mild clinical improvements in measures such as
swollen joint counts and Disease Activity Score in 28 Joints
(DAS28) scores [58]. Disease activity also improved in RA
patients undergoing a methotrexate regimen in combin-
ation with atorvastatin; evidence that inflammatory cyto-
kines such as TNF-α were decreased systemically provided
a potential mechanism to explain these observations [59]. A
different trial of atorvastatin in patients with RA revealed a
clinically apparent improvement in DAS28 scores as well as
a decrease in C-reactive protein and erythrocyte sedimenta-
tion, which are typical markers used to diagnose RA [60].
However, conflicting evidence regarding the effects of
statins has also arisen. Statins accelerated the effect of col-
lagen type II-induced arthritis in mice [61]. Furthermore,
statins may induce a pro-inflammatory response in per-
ipheral blood mononuclear cells by activating IL-18 and
caspase-1 [62]. Although rosuvastatin has been shown to
reduce C-reactive protein in patients with RA, this effect
did not correlate with an improvement in overall RA dis-
ease activity [63]. Therefore, statins may have both anti-
and pro-inflammatory effects, depending on the form and
progression of the disease, the type of statin prescribed,
and whether the patient is undergoing a multiple-drug
regimen. Further investigation into the effects of statins is
required in RA to clarify whether they are clinically effect-
ive anti-inflammatory treatments in human trials and
whether a corresponding reduction in aggrecanase activity
in RA is apparent.
Osteoarthritis
In OA chondrocyte cultures, atorvastatin produced a sig-
nificant reduction in IL-1β and MMP-13 as well as an in-
crease in aggrecan and ColIIa1 expression, and this is an
indication that atorvastatin may have chondroprotective
effects, as well as anti-inflammatory effects [64], which
could be relevant in the treatment of OA. This was also
demonstrated with mevastatin, which showed reduced in-
flammatory cell infiltration and IL-1β and matrix-
degrading enzyme (MMP-3 and MMP-13) expression in
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in a rat model of mechanically induced knee OA, simva-
statin produced anti-inflammatory and immunomodula-
tory effects via the inhibition of MMP-3, demonstrating
a possible additional chondroprotective effect [66].
Therefore, several classes of statins not only may have
anti-inflammatory effects but also may demonstrate
chondroprotective effects in patients with OA or RA.
Further investigations regarding the effects of statins
in patients with OA or RA are clearly required given
the likelihood of high incidences of co-morbidities with
hypercholesterolemia, cardiovascular disease, obesity,
and arthritis. However, given their apparent effectiveness
in reducing inflammation or cytokine activity or both, one
might hypothesize that affected joints of co-morbid pa-
tients undergoing a statin regimen could be inadvertently
protected from cartilage destruction (Figures 1 and 2) to
varying extents.
The development of small-molecule inhibitors of
the aggrecanases ADAMTS4 and ADAMTS5
Although there are several treatment options of varying
efficacy for arthritis, many alternatives are currently being
explored, especially those that selectively inhibit some
MMPs or, more specifically, the ADAMTS aggrecanases
(Table 2). Synthetic broad-spectrum MMP inhibitors such
as batimastat and marimastat showed promise as anti-
cancer therapies in the 1990s as they reduced tumor
growth and spread in various animal models [67-72].
However, after the advancement of these inhibitors into
phase II clinical trials, these inhibitors caused severe tox-
icity and advanced disease progression in several studies
[73-76]. This has led to a more targeted approach to de-
veloping MMP and ADAMTS inhibitors as therapeutic in-
terventions in disease.Table 2 The development of synthetic ADAMTS aggrecanase
Compound
Engineered N-TIMP-3 [82]
(2R)-N4-hydroxy-2-(3-hydroxybenzyl)-N1-[(1S,2R)-2-hydroxy-,3-dihydro-1H-inden
N-hydroxyformamides [85]
1,2,4-triazole-3-thiol scaffolds [86]
N-((8-Hydroxy-5-substituted-quinolin-7-yl)(phenyl)methyl)-2-phenyloxy/amino
5-((1H-Pyrazol-4-yl)methylene)-2-thioxothiazolidin-4-one [88]
4-(benzamido)-4-(1,3,4-oxadiazol-2-yl) butanoic acid [89]
1-sulfonylaminocyclopropanecarboxylates, N-substituted sulfonylamino-alkan
1,3,5-triazine core [91]
CRB017 (antibody against ancillary domain) [92]
AGG-523 (Pfizer Inc.)
Engineered and synthetic compounds are being developed to obtain selectivity tow
cartilage destruction in both rheumatoid arthritis and osteoarthritis. ADAMTS, A Dis
TIMP, tissue inhibitor of metalloproteinase.Tissue inhibitors of metalloproteinases
TIMPs are specific endogenous MMP and ADAMTS in-
hibitors and also are essential for homeostasis of the
joint and proper matrix turnover as described above.
There are four mammalian TIMPs, designated TIMP-1
through −4; TIMP-1 was discovered in 1985. TIMP-3,
unlike the other TIMPs, has a broad profile of inhibition
that includes ADAMTS4 and ADAMTS5. TIMP-3 acts
as a tumor suppressor and inhibitor of angiogenesis,
and Timp-3 homozygous-null mice present with en-
hanced TNF signaling and serum IL-6 levels [77], indi-
cating a key role for TIMP-3 in innate immunity.
Furthermore, Timp-3 knockout mice present with an in-
creased inflammatory response to antigen-induced arth-
ritis and increased aggrecan and collagen II degradation
with age [78,79]. TIMP-3 may be a suitable therapeutic
treatment for patients with arthritis to suppress not
only innate inflammatory cytokines in arthritis but also
ADAMTS4 and ADAMTS5. Their lack of selectivity pre-
cludes them as an adequate treatment option in their na-
tive form. However, truncated TIMP-3 (N-TIMP-3),
lacking its C-terminal domain, is a potent endogenous in-
hibitor of ADAMTS4 and ADAMTS5 with inhibition also
demonstrated toward MMP-1, MMP-2, and (to a lesser
extent) MMP-3 [80]. Furthermore, the thrombospondin
type-1 repeats of ADAMTS4 and ADAMTS5 promote
binding with N-TIMP-3 [81], providing further evidence
that N-TIMP-3 may effectively inhibit ADAMTS4 and
ADAMTS5 with high affinity. Moreover, by engineering
the reactive site through amino acid substitutions within
the N-terminus of N-TIMP-3, some selectivity toward
ADAMTS4 and ADAMTS5 has been gained without off-
target MMP inhibition [82], suggesting that with further
modifications TIMPs may be a powerful potential future
therapeutic.inhibitors
Target selectivity
ADAMTS4, ADAMTS5
-1-yl] butanediamides [83] ADAMTS4, ADAMTS5
ADAMTS4, ADAMTS5
ADAMTS5 > ADAMTS4
-acetamides [87] ADAMTS5 > ADAMTS4,
ADAMTS5 > ADAMTS4
ADAMTS4, ADAMTS5
ecarboxylates [90] ADAMTS5
ADAMTS5
ADAMTS5
ADAMTS4, ADAMTS5
ard the inhibition of the aggrecanases ADAMTS4 and ADAMTS5 to prevent
integrin-like And Metalloproteinase domain with Thrombospondin-1 repeats;
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The need to develop novel and selective aggrecanase
inhibitors has become increasingly essential to arthritis
research. A series of (2R)-N4-hydroxy-2-(3-hydroxybenzyl)-
N1-[(1S,2R)-2-hydroxy-,3-dihydro-1H-inden-1-yl] butane-
diamide derivatives have previously been developed as
potent and selective inhibitors of aggrecanase activity [83].
A 3-hydroxyl group on one of the inhibitors achieved se-
lectivity through hydrogen bonding with a threonine in the
S1 pocket of ADAMTS5; however, this threonine is con-
served in ADAMTS4, reducing the selectivity of these de-
rivatives. A valine residue replaces this threonine in active
sites of most of the MMPs, thereby achieving some selectiv-
ity toward the aggrecanases [84]. Recently, a series of novel
achiral N-hydroxyformamide inhibitors of ADAMTS4 and
ADAMTS5, which are highly selective and potent in vitro,
have emerged [85]. In addition, a new family of ADAMTS5
inhibitors such as non-hydroxamic inhibitors, which display
a 1,2,4-triazole-3-thiol scaffold as a putative zinc-binding
group, have reached a reasonable level of selectivity toward
ADAMTS5 [86].
N-((8-Hydroxy-5-substituted-quinolin-7-yl)(phenyl)meth
yl)-2-phenyloxy/amino-acetamide inhibitors have been syn-
thesized, and four of these inhibitors demonstrated greater
ADAMTS5 potency and selectivity over ADAMTS4 and
MMP-13 [87]. In addition, 5-((1H-Pyrazol-4-yl)methy-
lene)-2-thioxothiazolidin-4-one inhibitors have been
synthesized and have shown good selectivity of
ADAMTS5 over ADAMTS4 [88]. Yet another series of
compounds, α-glutamic acid scaffold based 4-(benza-
mido)-4-(1,3,4-oxadiazol-2-yl) butanoic acids, have been
designed and synthesized to inhibit the activity of both
ADAMTS4 and ADAMTS5 [89]. Furthermore, a series
of 1-sulfonylaminocyclopropanecarboxylates and N-
substituted sulfonylamino-alkanecarboxylates are po-
tent ADAMTS5 inhibitors with good selectivity over
MMPs such as MMP-1 [90]. More recently, potent and se-
lective novel ADAMTS5 inhibitor scaffolds which lacked a
zinc-binding motif and which contained a 1,3,5-triazine
core were designed [91].
A recent study ameliorated OA progression in a spon-
taneous OA mouse model by using intra-articular in-
jections of an anti-ADAMTS5 antibody (CRB0017),
showing the first evidence of a biological agent (antibody-
mediated targeting) used against ADAMTS5 to halt the
progression of OA (Figures 1 and 2) and a proof of
principle that inhibiting this enzyme might be a promising
therapeutic [92]. The aggrecanase inhibitor AGG-523
(Wyeth Pharmaceuticals, now part of Pfizer Inc., New
York, NY, USA), which inhibits both ADAMTS4 and
ADAMTS5, has undergone clinical trials for the treatment
of OA and may become a new OA drug in the near future.
Although it has yet to be established which aggrecanase is
predominant in human arthritis, ADAMTS4 inhibitorsstill may be beneficial, particularly if they inhibit ADAMTS5
concurrently (Figures 1 and 2 and Table 2).
Conclusions
Optimization and individualization of treatment strategies
for patients with arthritis are required, as current treat-
ments continue to fail in efficacy and often lead to serious
side effects in a significant number of patients with arthritis.
Ensuring that arthritis sufferers have the best treatment
regimens for their condition is paramount. First- and
second-line treatments, alongside combination therapy,
show promising advancements in the field. Further research
into prospective treatments, as well as into the mechanisms
underlying joint destruction, is imperative. Questions such
as which ADAMTS aggrecanase may have the most signifi-
cant role in arthritis remain unanswered; however, it is clear
that current and emerging therapeutics that could indir-
ectly or directly inhibit these enzymes often lead to favor-
able outcomes in arthritis sufferers. The plethora of
emerging small-molecule ADAMTS aggrecanase inhibitors
gives hope that some will be efficacious and tolerable and
that those that are specific to ADAMTS5 could be devel-
oped as novel therapeutics for arthritis patients in the near
future. Thus, ADAMTS aggrecanase inhibitors may well
become useful as both isolated and combinational therapies
for most types of arthritis.
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